Friday, 22 Jun 2018

You are here

IL-18 Binding Protein Effective in Adult-Onset Still's Disease

Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).

The treatment of Still's disease has been revolutionized by the observation that this inflammasomopathy can be more effectively managed by inhibitors of IL-1 and IL-6.  But the same mechanisms driving excess IL-1 production and excessive caspase activity are mirrored by IL-18. 

They enrolled 21 adults with AOSD plus fever or or elevated C-reactive protein (CRP) levels and were treated with tadekinig alfa 80 mg (10 patients)  or 160 mg (13 patients) subcutaneously three times per week for 12 weeks.

By week 3, half of those treated with either 80 mg or 160 mg achieved the predefined response criteria.

They found 155 treatment-emerging AEs were recorded, most of which were mild, resolved and one-third were were considered related to the study drug.  There were 3 serious AEs occurred, one possibly related to treatment (toxic optic neuropathy).

These early results suggest and acceptable safety profile and good efficacy and warrants further controlled trial investigation in AOSD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.

Does RA kill you? Let me count the ways….and what you can do about it

There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.

FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis

The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.

FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis

Today the U.S. Food and Drug Administration approved baricitinib (Oluminant) at the lower dose of 2 mg per day for use in adults with with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to commonly-used treatments known as TNF inhibitors.